- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04340700
Characterization of the Pharmacodynamic Response to Vaped THC
February 9, 2022 updated by: A. Eden Evins, Massachusetts General Hospital
This study aims to characterize the pharmacodynamic response to vaped THC in young adult, occasional cannabis users with respect to outcomes such as stimulation and sedative effects, mood, anxiety, and craving, as well as cognitive and objective outcomes such as heart rate and cortisol changes with THC vs placebo.
Study Overview
Detailed Description
Enrollees will include 120 healthy, weekly or greater MJ users, aged 18-55.
The study will be conducted according to a double-blind, placebo-controlled, random order, cross-over design, consisting of one 3-hour screening visit and 2 randomized, approximately 6-hour laboratory sessions.
At the latter visits (following confirmation of eligibility), subjects will complete baseline questionnaires and assessments, including a driver simulator test, a blood draw, vitals, and an imaging session using functional near-infrared spectroscopy (fNIRS).
Subjects will then vape a first dose (either THC or placebo based on randomization).
Vitals and questionnaires will then be administered throughout the visit, at baseline, and at approximately 15, 60, 90, 130, 165, and 210 minutes post initial dose.
Subjects will also perform fNIRS testing at baseline, 30, and 180 minutes and driver simulator at baseline, 60, and 90 minutes post initial THC/placebo administration.
A drug recognition expert (DRE) will conduct a standard field sobriety test to identify impairment at approximately 130 minutes post dose.
Following the initial dose vaped at 0 minutes, standardized reduced doses will be vaped approximately 30, 60, and 90 minutes later.
Given the cross-over design of this study, participants will be assigned to receive THC or placebo at the first laboratory visit and will receive the other substance at the second laboratory visit.
Study Type
Interventional
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Men and women aged 18-55 years, inclusive.
- Competent and willing to provide written informed consent.
- Able to communicate in English language.
- Regular, at least weekly on average, marijuana use
- Self-reported ability to abstain from cannabis for 24 hours without withdrawal.
Exclusion Criteria:
- Any unstable, serious medical illness or cardiovascular disease/events.
- New or unstable psychiatric symptoms, schizophrenia, or bipolar I disorder.
- Diabetes, cirrhosis, renal failure, Hepatitis C, or HIV.
- History of syncope without an identified situational stressor, migraines >1x/month, or head injury with prolonged unconsciousness (> 24 hours).
- Daily use of benzodiazepines or barbiturates, antihistamines, atropine, scopolamine, or other strong anticholinergic agents.
- Current pregnancy, lactation or trying to become pregnant (confirmed by urine pregnancy test).
- History of substance abuse treatment and intent to quit or receiving treatment for cannabis use.
- Affective disorder in the past month or history of panic attacks.
- Smoking more than 10 tobacco cigarettes or equivalent e-cigarettes a day.
- In the opinion of the investigator, not able to safely participate in this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: THC
A standard dose of THC (8 mg or 2 mg) will be placed in a Volcano Vaporizer chamber.
The first THC dose is 8 mg, followed by approximately three doses of 2 mg each.
|
A standard dose of THC (8 mg or 2 mg) will be placed in a Volcano Vaporizer chamber.
The first THC dose is 8 mg, followed by approximately three doses of 2 mg each.
Placebo will also be administered through a Volcano Vaporizer via inhalation.
The first placebo dose is 8 mg, followed by approximately three doses of 2 mg each to match the THC procedures.
|
Placebo Comparator: Placebo
Placebo will also be administered through a Volcano Vaporizer via inhalation.
The first placebo dose is 8 mg, followed by approximately three doses of 2 mg each to match the THC procedures.
|
A standard dose of THC (8 mg or 2 mg) will be placed in a Volcano Vaporizer chamber.
The first THC dose is 8 mg, followed by approximately three doses of 2 mg each.
Placebo will also be administered through a Volcano Vaporizer via inhalation.
The first placebo dose is 8 mg, followed by approximately three doses of 2 mg each to match the THC procedures.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Drug Effects Questionnaire
Time Frame: Pre-dose, and 15, 60, 90, 130, 165, 210 minutes post dose
|
This 15-item questionnaire measures drug effects, behavioral/mood states, and craving.
Each item is scored from 0-100, and all items are averaged for a total score from 0-100 with higher scores indicating greater drug effect.
|
Pre-dose, and 15, 60, 90, 130, 165, 210 minutes post dose
|
Change in Biphasic Alcohol Effects Scale (Modified for THC)
Time Frame: Pre-dose, and 15, 60, 90, 130, 165, 210 minutes post dose
|
This 14-item questionnaire measures stimulation and sedation.
The Stimulation subscale scores range from 7-70 with higher scores indicating greater stimulation.
The Sedation subscale scores range from 7-70 with higher scores indicating greater sedation.
|
Pre-dose, and 15, 60, 90, 130, 165, 210 minutes post dose
|
Change in The Spielberger State Anxiety Inventory
Time Frame: Pre-dose, and 15, 60, 90, 130, 165, 210 minutes post dose
|
This 20-item questionnaire measures state/current anxiety.
Scores range from 20-80 with higher scores indicating greater state anxiety.
|
Pre-dose, and 15, 60, 90, 130, 165, 210 minutes post dose
|
Change in Driving Simulation Performance on the Divided Attention Task (DAT)
Time Frame: Pre-dose, and 60 and 90 minutes post dose
|
A computer-programmed driving simulator will assess DAT performance using percentage impaired (from 0-100%).
|
Pre-dose, and 60 and 90 minutes post dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Functional Near-Infrared Spectroscopy (fNIRS) Brain Signal
Time Frame: Pre-dose, and 30 and 180 minutes post dose
|
fNIRS measures oxygenated hemoglobin (HbO) during both resting state and a working memory task in both THC and placebo conditions.
|
Pre-dose, and 30 and 180 minutes post dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Eden Evins, MD, MPH, Massachusetts General Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
November 1, 2022
Primary Completion (Anticipated)
October 1, 2025
Study Completion (Anticipated)
October 1, 2025
Study Registration Dates
First Submitted
March 23, 2020
First Submitted That Met QC Criteria
April 7, 2020
First Posted (Actual)
April 9, 2020
Study Record Updates
Last Update Posted (Actual)
February 11, 2022
Last Update Submitted That Met QC Criteria
February 9, 2022
Last Verified
February 1, 2022
More Information
Terms related to this study
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vaping
-
Philip Morris Products S.A.CompletedNicotine | Nicotine Vaping | VapingUnited Kingdom
-
St. Jude Children's Research HospitalRecruitingVaping | Vaping CessationUnited States
-
University of Massachusetts, WorcesterNational Cancer Institute (NCI)Not yet recruiting
-
University of RochesterNational Cancer Institute (NCI)Completed
-
Philip Morris Products S.A.CompletedNicotine | Nicotine Vaping | VapingUnited States
-
UNC Lineberger Comprehensive Cancer CenterNational Institute on Drug Abuse (NIDA); Food and Drug Administration (FDA)Recruiting
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA)Recruiting
-
UNC Lineberger Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH); Food and...Completed
-
Mayo ClinicWithdrawn
Clinical Trials on THC or Placebo
-
Hartford HospitalYale UniversityRecruiting
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)Completed
-
Yale UniversityNational Institute on Drug Abuse (NIDA); Hartford Hospital; National Highway...Active, not recruitingAlcohol Impairment | Marijuana ImpairmentUnited States
-
Tel Aviv Medical CenterRecruiting
-
Johns Hopkins UniversitySubstance Abuse and Mental Health Services Administration (SAMHSA)CompletedCannabis | Drug EffectUnited States
-
University of California, San DiegoCenter for Medicinal Cannabis ResearchNot yet recruiting
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)Recruiting
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)Not yet recruiting
-
Brown UniversityTerminatedRheumatoid Arthritis | Psoriatic ArthritisUnited States
-
University of California, San DiegoCenter for Medicinal Cannabis ResearchRecruitingHIV | Cannabis UseUnited States